Video
Dosing, Treatment Cycle During Phase 2 Trial Assessing Infigratinib for Treatment of Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the dosing and treatment cycle during the trial assessing infigratinib for the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.
Pharmacy Times interviewed Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, on the phase 2 trial results that led to the US FDA approval of infigratinib (Truseltiq, QED Therapeutics) for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
During this discussion, Javle addressed the dosing and treatment cycle during the trial.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
